Literature DB >> 19701733

[Scientific evidence and the cost of innovations in the health-care system].

Franz Porzsolt1, Jonas Schreyögg.   

Abstract

When depicting the relationship between evidence and the cost of an innovation in the health-care system, the overall risks of assessment, the redistribution of risks in a regulated market, and the ethical consequences must first be taken into account. There are also evidence-based criteria and economic considerations which are relevant when calculating the cost of an innovation. These topics can indicate, but not exhaustively deal with the complicated relationship between scientific evidence and calculating the cost of an innovation in the health-care system. The following three statements summarize the current considerations in the continuing discussion of this topic: *Scientific evidence undoubtedly exists which should be taken into consideration when calculating the cost of an innovation in the health-care system. *The existing scientific evidence is, however, not sufficient to reach such a decision. Additional information about the benefit perceived by the patient is required. *No standardized method exists to measure this additional information. Therefore, a definition problem also exists in the health-care system when setting a price according to scientific evidence.

Entities:  

Mesh:

Year:  2009        PMID: 19701733     DOI: 10.1007/s00063-009-1134-3

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  28 in total

1.  Match your innovation strategy to your innovation ecosystem.

Authors:  Ron Adner
Journal:  Harv Bus Rev       Date:  2006-04

2.  Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.

Authors:  Haiden A Huskamp
Journal:  Health Aff (Millwood)       Date:  2006 May-Jun       Impact factor: 6.301

3.  [Patient safety in hospitals--a health services research issue].

Authors:  M Schrappe
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2006-02       Impact factor: 1.513

4.  Technology assessment in the German context.

Authors:  Michael Drummond
Journal:  Eur J Health Econ       Date:  2007-09

5.  [Ethical and empirical limitations of randomized controlled trials].

Authors:  Franz Porzsolt; Hartmut Kliemt
Journal:  Med Klin (Munich)       Date:  2008-12-20

6.  The legal framework for health care quality assurance in Germany.

Authors:  Dirk Sauerland
Journal:  Health Econ Policy Law       Date:  2009-01

7.  IQWiG: an opportunity lost?

Authors:  Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2008-08

Review 8.  A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.

Authors:  Jan S A G Schouten; Ellen C La Heij; Carroll A B Webers; Igor J Lundqvist; Fred Hendrikse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-09       Impact factor: 3.117

9.  The missed lessons of Sir Austin Bradford Hill.

Authors:  Carl V Phillips; Karen J Goodman
Journal:  Epidemiol Perspect Innov       Date:  2004-10-04

10.  Setting priorities in health care organizations: criteria, processes, and parameters of success.

Authors:  Jennifer L Gibson; Douglas K Martin; Peter A Singer
Journal:  BMC Health Serv Res       Date:  2004-09-08       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.